EA201800499A1 - Ингибитор тирозинкиназы для лечения амиотрофного латерального склероза, композиция, лекарственное средство, набор - Google Patents

Ингибитор тирозинкиназы для лечения амиотрофного латерального склероза, композиция, лекарственное средство, набор

Info

Publication number
EA201800499A1
EA201800499A1 EA201800499A EA201800499A EA201800499A1 EA 201800499 A1 EA201800499 A1 EA 201800499A1 EA 201800499 A EA201800499 A EA 201800499A EA 201800499 A EA201800499 A EA 201800499A EA 201800499 A1 EA201800499 A1 EA 201800499A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lateral sclerosis
inhibitor
treatment
thyrozinkinase
medicine
Prior art date
Application number
EA201800499A
Other languages
English (en)
Other versions
EA038531B1 (ru
Inventor
Алан Мюсси
Жан-Пьер Кине
Колин Менсфилд
Original Assignee
Аб Сьянс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аб Сьянс filed Critical Аб Сьянс
Publication of EA201800499A1 publication Critical patent/EA201800499A1/ru
Publication of EA038531B1 publication Critical patent/EA038531B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Настоящее изобретение относится к способу лечения пациентов, страдающих неагрессивным или умеренно агрессивным боковым амиотрофическим склерозом (БАС) со скоростью роста показателя согласно переработанной Шкале нарушений функций при боковом амиотрофическом склерозе (ALSFRS-R) <1,1 балла в месяц до начала лечения, включающему введение ингибитора тирозинкиназ или ингибитора мастоцитов, в частности мазитиниба или его фармацевтически приемлемой соли или сольвата необязательно в сочетании по меньшей мере с одним действующим фармацевтическим ингредиентом.
EA201800499A 2016-03-25 2017-03-24 Способ лечения амиотрофного латерального склероза, применение фармацевтической композиции, содержащей мазитиниб EA038531B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16162490 2016-03-25
PCT/EP2017/057134 WO2017162884A1 (en) 2016-03-25 2017-03-24 Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation

Publications (2)

Publication Number Publication Date
EA201800499A1 true EA201800499A1 (ru) 2019-03-29
EA038531B1 EA038531B1 (ru) 2021-09-10

Family

ID=55637258

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201800499A EA038531B1 (ru) 2016-03-25 2017-03-24 Способ лечения амиотрофного латерального склероза, применение фармацевтической композиции, содержащей мазитиниб

Country Status (20)

Country Link
US (1) US10092564B2 (ru)
EP (1) EP3240538B1 (ru)
JP (2) JP7250312B2 (ru)
KR (1) KR102293847B1 (ru)
CN (1) CN108883108B (ru)
AU (1) AU2017236177B2 (ru)
BR (1) BR112018069515A2 (ru)
CA (1) CA3018635C (ru)
DK (1) DK3240538T3 (ru)
EA (1) EA038531B1 (ru)
ES (1) ES2899929T3 (ru)
HU (1) HUE057398T2 (ru)
IL (1) IL261856B (ru)
MX (1) MX2018011349A (ru)
NZ (1) NZ745778A (ru)
PL (1) PL3240538T3 (ru)
PT (1) PT3240538T (ru)
SG (1) SG11201808106YA (ru)
SI (1) SI3240538T1 (ru)
WO (1) WO2017162884A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP3563849A3 (en) 2012-10-25 2020-02-12 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
EP3060205A4 (en) 2013-10-22 2017-06-28 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CA3033079A1 (en) 2016-08-31 2018-03-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
EP3800471A1 (en) 2016-11-25 2021-04-07 Genuv Inc. Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same
KR20190128703A (ko) * 2017-03-28 2019-11-18 노파르티스 아게 다발 경화증 치료를 위한 새로운 방법
CN111328283A (zh) * 2017-05-30 2020-06-23 德西费拉制药有限责任公司 1-[4-溴-5-[1-乙基-7-(甲氨基)-2-氧代-1，2-二氢-1，6-萘啶-3-基]-2-氟苯基]-3-苯基脲和类似物用于治疗与血小板衍生的生长因子受体α中的遗传异常相关的癌症的用途
JP7463281B2 (ja) * 2018-03-05 2024-04-08 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド コロニー刺激因子を標的とすることによる、緑内障および視神経症のための療法
CN113038944A (zh) 2018-07-02 2021-06-25 通用医疗公司 色甘酸钠和α-乳糖的粉末化制剂
CN112618717A (zh) * 2019-09-24 2021-04-09 北京大学深圳研究生院 Btk抑制剂用于治疗肌萎缩侧索硬化症的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (ru) 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
ES2294344T3 (es) 2002-08-02 2008-04-01 Ab Science 2-(3-aminoaril)amino-4-aril-tiazoles y su utilizacion como inhibidores de c-kit.
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
WO2008098949A2 (en) 2007-02-13 2008-08-21 Ab Science Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors
AR080933A1 (es) 2010-04-20 2012-05-16 Ab Science Tratamiento de esclerosis multiple con masitinib
JP6145946B2 (ja) 2011-07-13 2017-06-14 サイトキネティックス， インコーポレイテッド 併用ａｌｓ療法
SI2903616T1 (en) * 2012-10-04 2018-02-28 Ab Science The use of masitinib in combination with gemcitabine for the treatment of a subgroup of patients suffering from foot-and-mouth disease
CA2902599C (en) * 2013-03-15 2023-03-21 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone compounds and methods of treating disorders
WO2015063318A1 (en) * 2013-11-04 2015-05-07 Ab Science Use of masitinib for treatment of amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
AU2017236177B2 (en) 2022-03-31
CA3018635C (en) 2023-09-26
CN108883108A (zh) 2018-11-23
SG11201808106YA (en) 2018-10-30
BR112018069515A2 (pt) 2019-04-16
EP3240538B1 (en) 2021-09-29
PL3240538T3 (pl) 2022-01-31
IL261856B (en) 2022-04-01
AU2017236177A1 (en) 2018-09-20
EP3240538A1 (en) 2017-11-08
US10092564B2 (en) 2018-10-09
KR20180125966A (ko) 2018-11-26
EA038531B1 (ru) 2021-09-10
JP2022037132A (ja) 2022-03-08
PT3240538T (pt) 2021-12-07
SI3240538T1 (sl) 2022-02-28
US20180117037A1 (en) 2018-05-03
JP2019515884A (ja) 2019-06-13
CA3018635A1 (en) 2017-09-28
WO2017162884A1 (en) 2017-09-28
CN108883108B (zh) 2021-08-06
KR102293847B1 (ko) 2021-08-26
IL261856A (en) 2018-10-31
DK3240538T3 (da) 2021-12-06
MX2018011349A (es) 2019-02-07
NZ745778A (en) 2022-07-01
JP7250312B2 (ja) 2023-04-03
HUE057398T2 (hu) 2022-05-28
ES2899929T3 (es) 2022-03-15

Similar Documents

Publication Publication Date Title
EA201800499A1 (ru) Ингибитор тирозинкиназы для лечения амиотрофного латерального склероза, композиция, лекарственное средство, набор
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX2021004431A (es) Procesos novedosos.
PH12020551425A1 (en) Rimegepant for cgrp related disorders
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
MA40240A (fr) Composés hétéroaryle d&#39;inhibition de la kinase
MX2016014634A (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
TW201613919A (en) Inhibitors of Bruton&#39;s tyrosine kinase
MX2021007651A (es) Inhibidores de ezh2 para tratar linfomas.
WO2016109217A3 (en) Btk inhibitors
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
MA39765A (fr) Formulation pharmaceutique d&#39;un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d&#39;utilisation
JOP20190233A1 (ar) نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
EP4279127A3 (en) Growth differentiation factor 15 as biomarker for metformin
MX2021013602A (es) Inhibidores de jak.
MX2021009539A (es) Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina.
PH12018501285A1 (en) Alkyl dihydroquinoline sulfonamide compounds
PH12017501668A1 (en) Bace1 inhibitors
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MX2018007511A (es) Compuestos de alquinil dihidroquinolina sulfonamida.
MX2016008968A (es) Compuestos organicos.
PH12021550671A1 (en) Prodrugs of cgrp antagonists